Latest Headlines

Latest Headlines

Anthrax vax to move into new Phase II trials

PharmaThene, supported with federal funding, is developing an anti-bioterrorism anthrax vaccine, SparVax, and is planning further Phase II trials for the second half of 2012.

PharmAthene wins ruling in fight over $78M anthrax contract

PharmAthene announced that it won a brawl with rival Emergent BioSolutions, obtaining a ruling from the Government Accountability Office that allows the developer to keep a $78 million contract to